T45.602 Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm

Name of the Condition

• Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm (ICD-10 code: T45.602)

Summary

This condition involves intentional self-harm through exposure to unspecified fibrinolysis-affecting drugs, which disrupt the body’s clot-dissolving processes. These drugs target fibrinolysis, and intentional poisoning can lead to harmful effects, including bleeding or systemic complications. The term "unspecified" indicates the exact drug is not identified, while "intentional self-harm" denotes deliberate exposure.

Causes

Intentional self-harm occurs when an individual deliberately ingests, injects, or is exposed to fibrinolysis-affecting drugs. This may result from suicidal intent, misuse, or intentional overdose. Underlying factors like mental health conditions, substance use, or access to these medications can contribute.

Risk Factors

• Access to fibrinolysis-affecting drugs (e.g., in clinical or household settings).
• History of suicidal ideation or prior self-harm attempts.
• Concurrent mental health disorders (e.g., depression, anxiety).
• Substance use disorders involving prescription or illicit drugs.
• Lack of supervision or secure storage of medications.

Symptoms

• Uncontrolled or excessive bleeding (e.g., bruising, nosebleeds, gastrointestinal bleeding).
• Prolonged bleeding from minor injuries.
• Low blood pressure or shock in severe cases.
• Abdominal pain or swelling.
• Dizziness, confusion, or loss of consciousness.

Diagnosis

Diagnosis involves clinical evaluation of symptoms, history of intentional exposure, and laboratory tests to assess bleeding risk (e.g., coagulation studies). Toxicology screening may identify fibrinolysis-affecting drugs, though "unspecified" indicates the exact agent is unknown. Imaging or other tests may be used to evaluate complications like internal bleeding.

Treatment Options

Treatment focuses on stabilizing the patient, managing bleeding, and addressing the underlying self-harm. Interventions may include:

• Reversal agents (if available) to counteract fibrinolysis effects.
• Blood product transfusions to control bleeding.
• Supportive care (e.g., fluid resuscitation, monitoring).
• Psychiatric evaluation and intervention for self-harm.

Prognosis and Follow-Up

Prognosis depends on the severity of exposure, timely treatment, and underlying mental health status. Early intervention improves outcomes, but severe bleeding or delayed care can lead to complications. Follow-up includes monitoring for bleeding, psychiatric support, and addressing medication access or storage.

Complications

• Severe or life-threatening bleeding (e.g., intracranial hemorrhage).
• Organ damage from prolonged bleeding or shock.
• Long-term psychological effects of self-harm.
• Recurrence of intentional exposure if underlying issues are unaddressed.

Lifestyle & Prevention

• Secure storage of medications to prevent access.
• Education on drug risks and proper disposal.
• Mental health support for individuals at risk of self-harm.
• Regular psychiatric follow-up for those with prior attempts.

When to Seek Professional Help

Seek immediate medical attention if intentional exposure to fibrinolysis-affecting drugs is suspected, or if symptoms like uncontrolled bleeding, dizziness, or loss of consciousness occur. Prompt care is critical to prevent severe complications.

Tips for Medical Coders

Document the intent (intentional self-harm) and specify "unspecified" for the drug when the exact agent is unknown. Include details on exposure circumstances, clinical findings, and treatment to support code assignment. Ensure alignment with ICD-10-CM guidelines for poisoning and self-harm codes.